On May 9, 2025, Guggenheim analyst Jason Cassorla announced an update for Ardent Health Partners (ARDT, Financial). The analyst maintained a "Buy" rating on the stock, reinforcing confidence in the company's potential.
Alongside the rating confirmation, Cassorla increased the price target for ARDT. The new price target is set at $18.00 USD, up from the previous target of $16.00 USD. This adjustment represents a 12.50% increase, suggesting positive expectations for the stock's future performance.
The updated rating and price target underscore Guggenheim's positive outlook for Ardent Health Partners (ARDT, Financial), reflecting anticipated growth and potential value in the market.